The opportunistic entrepreneur

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ross Burn, Chief Executive at CatSci. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ross, covering: Creating a successful business from an opportunistic AZ spin-out. Never being afraid to pivot in-line with the needs of the market and have big aims like becoming an innovative medicines development partner with a $1 billion valuation. The challenge of raising capital as an oversubscribed CRO with a 50% compound growth rate. How the pandemic has helped put life sciences and pharma R&D on the map but also the work to be done to meet unmet needs. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed. We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com